NSCLC molecular testing in Central and Eastern European countries

Ryska, Ales; Berzinec, Peter; Brcic, Luka; Cufer, Tanja; Dziadziuszko, Rafal; Gottfried, Maya; Kovalszky, Ilona; Olszewski, Wlodzimierz; Oz, Ayşim; Plank, Lukas; Timar, Jozsef

doi:10.1186/s12885-018-4023-4

NSCLC molecular testing in Central and Eastern European countries

Ryska A., Berzinec P., Brcic L., Cufer T., Dziadziuszko R., Gottfried M., ...Daha Fazla

BMC CANCER, cilt.18, 2018 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 18
Basım Tarihi: 2018
Doi Numarası: 10.1186/s12885-018-4023-4
Dergi Adı: BMC CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
İstanbul Üniversitesi Adresli: Evet

Özet

Background: The introduction of targeted treatments for subsets of non-small cell lung cancer (NSCLC) has highlighted the importance of accurate molecular diagnosis to determine if an actionable genetic alteration is present. Few data are available for Central and Eastern Europe (CEE) on mutation rates, testing rates, and compliance with testing guidelines.